These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Medication, logic, and schizophernic thinking: a reply to Marini. Ho DY J Genet Psychol; 1976 Sep; 129(1st Half):93-5. PubMed ID: 9471 [TBL] [Abstract][Full Text] [Related]
3. Being rational. Stefanidis E Schizophr Bull; 2006 Jul; 32(3):422-3. PubMed ID: 16192408 [No Abstract] [Full Text] [Related]
4. [Pharmacologic treatment of the psychotic symptoms in schizophrenia]. Goldchluk A Vertex; 2002; 13 Suppl 1():4-11. PubMed ID: 12122421 [TBL] [Abstract][Full Text] [Related]
5. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM; Franco S J Clin Psychiatry; 1991 Jan; 52(1):26-30. PubMed ID: 1671032 [TBL] [Abstract][Full Text] [Related]
6. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
7. Substance abuse and the management of medication nonadherence in schizophrenia. Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865 [TBL] [Abstract][Full Text] [Related]
12. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Chang SC; Chen CH; Lu ML Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544 [TBL] [Abstract][Full Text] [Related]
13. The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. Simhandl C; Meszaros K J Psychiatry Neurosci; 1992 Mar; 17(1):1-14. PubMed ID: 1349823 [TBL] [Abstract][Full Text] [Related]
14. The effects of clozapine on aggression and substance abuse in schizophrenic patients. Volavka J J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611 [TBL] [Abstract][Full Text] [Related]
15. The CATIE study and its implications for antipsychotic drug use. Janicak PG Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293 [No Abstract] [Full Text] [Related]
16. [Current concepts of pharmacological treatment in schizophrenia]. Jarema M Psychiatr Pol; 2002; 36(6):857-68. PubMed ID: 12725017 [TBL] [Abstract][Full Text] [Related]
17. Schizophrenic psychology, associative learning and the role of forebrain dopamine. Miller R Med Hypotheses; 1976; 2(5):203-11. PubMed ID: 9558 [TBL] [Abstract][Full Text] [Related]
18. Interictal psychoses in comparison with schizophrenia--a prospective study. Tadokoro Y; Oshima T; Kanemoto K Epilepsia; 2007 Dec; 48(12):2345-51. PubMed ID: 17666070 [TBL] [Abstract][Full Text] [Related]
19. Change in "overinclusive" thinking of schizophrenic patients is related to plasma phenothiazine concentration. Phillipson OT; Baker J; Williams M Adv Biochem Psychopharmacol; 1980; 24():591-7. PubMed ID: 6105805 [No Abstract] [Full Text] [Related]
20. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]